Redcare Pharmacy

Deutsche Bank Research has raised the price target for Redcare Pharmacy from €103 to €104 and kept the rating at "Buy." Analyst Jan Koch says the prescription business in Germany remains strong and expects a recovery in sales of non-prescription products in the third quarter. He considers the confirmed operating profit margin to be conservative. » More on finanzen.net

Online pharmacy Redcare Pharmaceuticals has raised its 2026 revenue forecast to +16–18% (previously 15–17%). The expected operating profit margin remains at 2.5–3.0%. The company cites the rapidly growing e-prescription segment in Germany as the main driver; the stock was firmer on Tuesday. » More on finanzen.net

Redcare Pharmacy increases its 2026 revenue forecast to growth of 16–18% and confirms an adjusted EBITDA margin of 2.5–3.0%. Revenues from prescription medicines in Germany are now expected to reach €730–760 million in 2026 (growth 45–51%). In the third quarter, these sales preliminarily rose by 56%; over-the-counter products recovered after a weak July. The stock jumped intraday by up to 14% and was around 12% higher in the afternoon. » More on finanzen.net